结构明确的去泛素酶抑制剂为研究疾病机制提供了机会

Q1 Pharmacology, Toxicology and Pharmaceutics Drug Discovery Today: Technologies Pub Date : 2019-04-01 DOI:10.1016/j.ddtec.2019.02.003
Ingrid E. Wertz , Jeremy M. Murray
{"title":"结构明确的去泛素酶抑制剂为研究疾病机制提供了机会","authors":"Ingrid E. Wertz ,&nbsp;Jeremy M. Murray","doi":"10.1016/j.ddtec.2019.02.003","DOIUrl":null,"url":null,"abstract":"<div><p>The Ubiquitin/Proteasome System comprises an essential cellular mechanism for regulated protein degradation. Ubiquitination may also promote the assembly of protein complexes that initiate intracellular signaling cascades. Thus, proper regulation of substrate protein ubiquitination is essential for maintaining normal cellular physiology. Deubiquitinases are the class of enzymes responsible for removing ubiquitin modifications from target proteins and have been implicated in regulating human disease. As such, deubiquitinases are now recognized as emerging drug targets. Small molecule deubiquitinase inhibitors have been developed; among those, inhibitors for the deubiquitinases USP7 and USP14 are the best-characterized given that they are structurally validated. In this review we discuss the normal physiological roles of the USP7 and USP14 deubiquitinases as well as the pathological conditions associated with their dysfunction, with a focus on oncology and neurodegenerative diseases. We also review structural biology of USP7 and USP14 enzymes and the characterization of their respective inhibitors, highlighting the various molecular mechanisms by which these deubiquitinases may be functionally inhibited. Finally, we summarize the cellular and <em>in vivo</em> studies performed using the structurally-validated USP7 and USP14 inhibitors.</p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":"31 ","pages":"Pages 109-123"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2019.02.003","citationCount":"35","resultStr":"{\"title\":\"Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms\",\"authors\":\"Ingrid E. Wertz ,&nbsp;Jeremy M. Murray\",\"doi\":\"10.1016/j.ddtec.2019.02.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The Ubiquitin/Proteasome System comprises an essential cellular mechanism for regulated protein degradation. Ubiquitination may also promote the assembly of protein complexes that initiate intracellular signaling cascades. Thus, proper regulation of substrate protein ubiquitination is essential for maintaining normal cellular physiology. Deubiquitinases are the class of enzymes responsible for removing ubiquitin modifications from target proteins and have been implicated in regulating human disease. As such, deubiquitinases are now recognized as emerging drug targets. Small molecule deubiquitinase inhibitors have been developed; among those, inhibitors for the deubiquitinases USP7 and USP14 are the best-characterized given that they are structurally validated. In this review we discuss the normal physiological roles of the USP7 and USP14 deubiquitinases as well as the pathological conditions associated with their dysfunction, with a focus on oncology and neurodegenerative diseases. We also review structural biology of USP7 and USP14 enzymes and the characterization of their respective inhibitors, highlighting the various molecular mechanisms by which these deubiquitinases may be functionally inhibited. Finally, we summarize the cellular and <em>in vivo</em> studies performed using the structurally-validated USP7 and USP14 inhibitors.</p></div>\",\"PeriodicalId\":36012,\"journal\":{\"name\":\"Drug Discovery Today: Technologies\",\"volume\":\"31 \",\"pages\":\"Pages 109-123\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ddtec.2019.02.003\",\"citationCount\":\"35\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today: Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1740674918300477\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Technologies","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1740674918300477","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 35

摘要

泛素/蛋白酶体系统是调节蛋白质降解的重要细胞机制。泛素化也可能促进蛋白质复合物的组装,从而引发细胞内信号级联反应。因此,适当调节底物蛋白泛素化对于维持正常的细胞生理是必不可少的。去泛素酶是一类负责从靶蛋白中去除泛素修饰的酶,并与调节人类疾病有关。因此,去泛素酶现在被认为是新兴的药物靶点。小分子去泛素酶抑制剂已经开发出来;其中,去泛素酶USP7和USP14的抑制剂是最具特征的,因为它们在结构上得到了验证。在这篇综述中,我们讨论了USP7和USP14去泛素酶的正常生理作用,以及与它们功能障碍相关的病理情况,重点是肿瘤和神经退行性疾病。我们还回顾了USP7和USP14酶的结构生物学以及它们各自抑制剂的特性,强调了这些去泛素酶可能被功能抑制的各种分子机制。最后,我们总结了使用结构验证的USP7和USP14抑制剂进行的细胞和体内研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms

The Ubiquitin/Proteasome System comprises an essential cellular mechanism for regulated protein degradation. Ubiquitination may also promote the assembly of protein complexes that initiate intracellular signaling cascades. Thus, proper regulation of substrate protein ubiquitination is essential for maintaining normal cellular physiology. Deubiquitinases are the class of enzymes responsible for removing ubiquitin modifications from target proteins and have been implicated in regulating human disease. As such, deubiquitinases are now recognized as emerging drug targets. Small molecule deubiquitinase inhibitors have been developed; among those, inhibitors for the deubiquitinases USP7 and USP14 are the best-characterized given that they are structurally validated. In this review we discuss the normal physiological roles of the USP7 and USP14 deubiquitinases as well as the pathological conditions associated with their dysfunction, with a focus on oncology and neurodegenerative diseases. We also review structural biology of USP7 and USP14 enzymes and the characterization of their respective inhibitors, highlighting the various molecular mechanisms by which these deubiquitinases may be functionally inhibited. Finally, we summarize the cellular and in vivo studies performed using the structurally-validated USP7 and USP14 inhibitors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug Discovery Today: Technologies
Drug Discovery Today: Technologies Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
自引率
0.00%
发文量
0
期刊介绍: Discovery Today: Technologies compares different technological tools and techniques used from the discovery of new drug targets through to the launch of new medicines.
期刊最新文献
Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches Application of proteomic data in the translation of in vitro observations to associated clinical outcomes Advances in sample preparation for membrane proteome quantification Application of proteomics to understand maturation of drug metabolizing enzymes and transporters for the optimization of pediatric drug therapy Data-independent acquisition (DIA): An emerging proteomics technology for analysis of drug-metabolizing enzymes and transporters
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1